An immune checkpoint score system for prognostic evaluation and adjuvant chemotherapy selection in gastric cancer
Menée à partir d'échantillons tumoraux prélevés sur 124 puis 670 patients atteints d'un cancer gastrique, cette étude évalue la performance d'un système de score, basé sur l'expression de 6 ligands immunosuppresseurs (NECTIN2, CEACAM1, HMGB1, SIGLEC6, CD44 et CD155), pour établir un pronostic et identifier les patients pouvant bénéficier d'une chimiothérapie adjuvante
Immunosuppressive molecules are extremely valuable prognostic biomarkers across different cancer types. However, the diversity of different immunosuppressive molecules makes it very difficult to accurately predict clinical outcomes based only on a single immunosuppressive molecule. Here, we establish a comprehensive immune scoring system (ISSGC) based on 6 immunosuppressive ligands (NECTIN2, CEACAM1, HMGB1, SIGLEC6, CD44, and CD155) using the LASSO method to improve prognostic accuracy and provide an additional selection strategy for adjuvant chemotherapy of gastric cancer (GC). The results show that ISSGC is an independent prognostic factor and a supplement of TNM stage for GC patients, and it can improve their prognosis prediction accuracy; in addition, it can distinguish GC patients with better prognosis from those with high prognostic nutritional index score; furthermore, ISSGC can also be used as a tool to select GC patients who would benefit from adjuvant chemotherapy independent of their TNM stages, MSI status and EBV status.
Nature Communications , article en libre accès, 2020